Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Despite several big deals that buoyed the numbers, North America early- and seed-stage investment declined to multiquarter ...

Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Viking (VKTX) stock, Structure (GPCR) stock and others surge after Pfizer’s obesity drug setback. Read more here.

Tankup Engineers IPO consists of a fresh issue of 13,95,000 equity shares, aggregating to ₹19.53 crore. There's no offer for sale (OFS) component. Tankup Engineers IPO aims to use the net ...

Upcoming IPO: LG Electronics India, the Indian branch of the South Korean conglomerate, is anticipated to present the updated draft red herring prospectus (UDRHP) for its ₹15,000 crore IPO to ...

What is the current share price of Metsera Inc (MTSR)? Metsera Inc's (MTSR) current share price is $19.57. This constitutes a price movement of 49.62% when compared to the share price 7 days ago and ...

Metsera, Inc. (NASDAQ:MTSR – Free Report) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March ...

In a compelling validation of InvestingPro’s Fair Value analysis capabilities, Metsera , Inc. (NASDAQ:MTSR) has declined 44% since being identified as significantly overvalued by our proprietary ...